Klaria Pharma Holding AB (publ)
STO:KLAR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Klaria Pharma Holding AB (publ)
Operating Income
Klaria Pharma Holding AB (publ)
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
K
|
Klaria Pharma Holding AB (publ)
STO:KLAR
|
Operating Income
-kr25.2m
|
CAGR 3-Years
23%
|
CAGR 5-Years
12%
|
CAGR 10-Years
-16%
|
|
|
Orexo AB
STO:ORX
|
Operating Income
-kr352.7m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-82%
|
CAGR 10-Years
-12%
|
|
|
Camurus AB
STO:CAMX
|
Operating Income
kr873.9m
|
CAGR 3-Years
138%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
S
|
Swedencare AB (publ)
STO:SECARE
|
Operating Income
kr140.6m
|
CAGR 3-Years
5%
|
CAGR 5-Years
28%
|
CAGR 10-Years
32%
|
|
|
I
|
Infant Bacterial Therapeutics AB
STO:IBT B
|
Operating Income
-kr69m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
|
I
|
InDex Pharmaceuticals Holding AB
STO:FLERIE
|
Operating Income
-kr32.4m
|
CAGR 3-Years
32%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
Klaria Pharma Holding AB (publ)
Glance View
Klaria Pharma Holding AB engages in the development and commercialization of pharmaceutical products for migraine and cancer-related pain. The company is headquartered in Uppsala, Uppsala. The company went IPO on 2015-10-21. Through its group subsidiaries, the Company is active in developing and commercializing therapeutic drugs and treatment methods in the fields of migraine and pain related to cancer based on a patented drug delivery platform in the form of an alginate-based polymer film, which facilitates rapid and reliable transmucosal absorption via a muco-adhesive film. The firm operates Klaria Pharma AB as a wholly owned subsidiary.
See Also
What is Klaria Pharma Holding AB (publ)'s Operating Income?
Operating Income
-25.2m
SEK
Based on the financial report for Dec 31, 2025, Klaria Pharma Holding AB (publ)'s Operating Income amounts to -25.2m SEK.
What is Klaria Pharma Holding AB (publ)'s Operating Income growth rate?
Operating Income CAGR 10Y
-16%
Over the last year, the Operating Income growth was 19%. The average annual Operating Income growth rates for Klaria Pharma Holding AB (publ) have been 23% over the past three years , 12% over the past five years , and -16% over the past ten years .
